Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NALSCY
- Development stage
- Preclinical
- Lead developer
- Cassava Sciences
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
**NALSCY** is an investigational fixed-dose sublingual formulation of **buprenorphine + naloxone** developed for opioid dependence. Buprenorphine is a high-affinity partial agonist at the mu-type opioid receptor, reducing opioid withdrawal symptoms and cravings while limiting the pharmacology of full opioid agonists. Naloxone is an opioid-receptor antagonist included primarily to deter parenteral misuse; it has limited bioavailability by the intended sublingual route. Pain Therapeutics licensed European development and commercialization rights to SWYX Pharma while retaining United States rights.
- Other names
- NALSCY
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on NALSCY.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NALSCY.